Last reviewed · How we verify
Naïve patients - MNDL therapy
MNDL therapy involves the use of a specific compound to target and modulate the activity of a particular enzyme.
MNDL therapy involves the use of a specific compound to target and modulate the activity of a particular enzyme. Used for Treatment of non-alcoholic steatohepatitis (NASH).
At a glance
| Generic name | Naïve patients - MNDL therapy |
|---|---|
| Sponsor | National Liver Institute, Egypt |
| Drug class | Hepatoprotective agent |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of MNDL therapy is not well understood, but it is believed to involve the inhibition of a specific enzyme involved in the progression of liver disease. This inhibition leads to a reduction in liver inflammation and fibrosis, ultimately slowing the progression of liver disease.
Approved indications
- Treatment of non-alcoholic steatohepatitis (NASH)
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naïve patients - MNDL therapy CI brief — competitive landscape report
- Naïve patients - MNDL therapy updates RSS · CI watch RSS
- National Liver Institute, Egypt portfolio CI